Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

156.15 -1.10 (-0.70%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,411,853
Open 157.29
Bid (Size) 154.66 (1)
Ask (Size) 156.16 (2)
Prev. Close 157.25
Today's Range 156.06 - 157.47
52wk Range 140.68 - 168.85
Shares Outstanding 2,628,679,824
Dividend Yield 3.18%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study
Sanofi and J&J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi's Q4 2024 IFRS EPS dropped by €0.15 following a $250M charge. 
Via Benzinga
Congress Member Josh Gottheimer Dumps Nvidia, Microsoft, Loads Up On Tesla Stocks Instead
Josh Gottheimer disclosed dozens of recent stock transactions including selling Nvidia stock and buying Tesla stock. 
Via Benzinga

Performance

YTD
+8.42%
+8.42%
1 Month
+5.67%
+5.67%
3 Month
+0.89%
+0.89%
6 Month
-2.18%
-2.18%
1 Year
-0.26%
-0.26%

More News

Read More
P/E Ratio Insights for Johnson & Johnson
Via Benzinga
Johnson & Johnson Explores Sale of Stroke Device Maker Cerenovus As MedTech Overhaul Accelerates
Via Benzinga
What's a Fair Price to Buy Johnson & Johnson Stock?
Via The Motley Fool
Warren Buffett's Granddaughter Claimed He Cut Her Off And She Couldn't Afford Health Insurance: 'He Disowned My Twin Sister And Myself'
Via Benzinga
2 Stocks to Buy if There Is a Market Crash in 2025
Via The Motley Fool
(JNJ) - Analyzing Johnson & Johnson's Short Interest
Via Benzinga
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
Via Benzinga
Kenvue's Q4 Sales Miss, Margins Improve
Via The Motley Fool
Topics Earnings
Exposures Financial
Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q4 Results Tomorrow
Via StockStory
What To Expect From Eli Lilly’s (LLY) Q4 Earnings
Via StockStory
Is Johnson & Johnson Stock a Buy?
Via The Motley Fool
Johnson & Johnson's Options Frenzy: What You Need to Know
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference
From Johnson & Johnson
Via Business Wire
Can Biotech Stocks Survive The Precarious Macro?
Via Talk Markets
Topics Stocks / Equities World Trade
Exposures Tariff
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
Via MarketBeat
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?
Via The Motley Fool
Did Johnson & Johnson Just Give Investors 23 Billion Reasons to Buy Its Stock?
Via The Motley Fool
The Dogs Of The Dow 2025
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Johnson & Johnson (NYSE:JNJ) Posts Q4 Sales In Line With Estimates
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Via Benzinga
Topics Government
Exposures Political
Starbucks To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.